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Abstract  Triple  negative  breast  cancer  (TNBC)  is  a  subtype  of  breast  cancer  (BC)  with  a  hetero-
geneous nature  that  stains  negatively  for  estrogen  receptor  (ER),  progesterone  receptor  (PR)
and human  epidermal  growth  factor  2 (HER2)  during  immunohistochemistry.  Approximately
15--20% of  all cases  of  breast  cancer  are triple  negative  phenotypes.  Compared  to  patients  with
hormone receptor-positive  cancer,  TNBC  patients  are  typically  younger  (<50  years),  African
American,  and  have a  high  incidence  of  mutations  in  BRCA1/2  genes.  To  date,  not  a  single  tar-
geted therapy  has been  approved  for  TNBC  treatment,  and  cytotoxic  chemotherapy  remains
as the  standard  systemic  treatment,  meaning  that  TNBC  is an aggressive  subtype  of  breast
cancer with  a  poor  prognosis.  In  this review,  the  literature  search  was  done  up  to  date  on
which gene expression  profile  of  TNBC  has been  analyzed  in  order  to  identify  the consensus
on molecular  mechanisms  involved  in  carcinogenesis  and/or  the  prognostic  markers  of  the
disease. In  conclusion,  these  studies  have  reported  that  TNBC  is composed  of several  clus-
ters or  genomic  signatures  as  basal  keratins.  They  have  also  reported  on  their  proliferation,
luminal/basal  apocrine,  regulatory  interferon,  immune  cells/immunoglobulin  related  to  stem
cells, epithelial-mesenchymal,  androgen  receptor  and  angiogenesis.  However,  not  all  research
groups  have  reported  reproducible  results.  This  confirms  the  heterogeneous  nature  of  TNBC
and the  need  for  research  on uniform  selection  criteria.  However,  these  discoveries  have  led
to the  proposal  of  new treatments,  such  as the  addition  of  platinum  salts,  new  combinations
of therapeutic  agents,  some  targeted  therapies  such  as  PARP  inhibitors,  and  PI3K  and  androgen
antagonists.  There  is no doubt  that  a  better  understanding  of  the  nature  of  TNBC  will  allow
individualized  and  more  effective  therapies.
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Introduction
Breast  cancer  (BC) is  the  main  cause  of  death  by  cancer
among  women,  and represents  30%  of  all new  cancer  cases
in  the  Caucasian  population.  A woman  living  in the United
States  has  a 12.3%  (1 in every  8)  risk  of being  diagnosed  with
breast  cancer.1 According  to  the  World  Health  Organization,
1.67  million  new  cases  were  registered  worldwide  in 2012.2
In  Mexico,  BC  is  also  the first  place  in malignant  neoplasia
incidence  among  women.  It  represents  11.34% of  all  cancer
cases,  with  a  global  increase  of  approximately  1.5%  annually.
However,  in  emerging  countries  this  increase  is  up  to  5%.3
Despite  having  the  same  origin  tissue,  BC  represents  a
heterogeneous  cancer  group  with  complex  biological  behav-
ior and  a  great  clinical  variability.  Over  the last  10  years,
extensive  research  at  a  molecular  and genetic  level  has  been
conducted  in  order  to  sub-type  these  BCs.  This  has  permitted
the  determination  of  clinical,  pathological  and molecular
variables,  to  select  treatment  modalities  and  forecast,  in
some  cases,  the  evolution  of  the disease  at the  moment  of
diagnosis.4
Breast cancer classification
In  the  traditional  way  the  most  important  information  that
pathologists  gave  oncologists,  respect  to  the  classification  of
breast  cancer,  included  the status  of  the nodules  and  tumor
size,  histological  grade  and  standard  immunohistochemistry
tests  (IHC)  status  of  hormone  receptors:  estrogen  receptor
(ER)  and  progesterone  receptor  (PR)  (Fig.  1).
Later  on,  in  the era of trastuzumab,  information  on  the
amplification  status  of the  human  epidermal  growth  factor
receptor  2 gene  (HER2)  became  routine.  Combining  all  these
parameters,  it was  possible  to  classify  patients  as  high  or  low
risk.  There  were  however  a  group  of patients  who  were  in an
intermediate  category  that  could  not be classified  between
these  two  groups.  Results  showed  that  15%  of  the  patients
classified  as  low risk  had  relapsed  or  died  due  to  a very
aggressive  disease.  And patients  classified  as  high  risk,  sur-
prisingly  10--15%  had a favorable  response.  All those  results
led  to  the  conclusion  that  the  method  of classification  was
not  very  appropriate.
Thus, based only  on  standard  IHC  directed  at cellular
markers  that  reflect the  availability  of  targeted  therapies,
breast  cancer  can  also  be  classified  into  three  main  groups:
(a)  homone  sensitive  (ER or  PR  positive),  (b)  HER2  positive,
sensitive  to  trastuzumab  or  (c)  triple  negative  breast  can-
cer  (TNBC),  defined  by  the absence  of ER, PR  and  HER2
amplification.5--8
No  targeted  treatment  is  available  for  TNBT  and
chemotherapy  remains  the  best  therapeutic  option.  How-
ever,  in the case  of  recurrence  or  chemoresistance,
therapeutic  options  are very  limited.9
Subsequently,  in  the late  90s,  when platforms  for
genomic  studies  were  available,  IHC  methods  coupled  with
complementary  DNA  (cDNA)  microarray  technology,  allowed
for  a more  extensive  BC  classification  and  were  able  to
define  four different  BC  subgroups,  which  differ  in prognosis
and  targets:  (a)  luminal  A --  positive  to  ER and PR,  negative
to  the amplification  of  HER2,  with  a  low  proliferation  index
(Ki-67  <  14%);  (b)  luminal  B --  ER  positive,  HER2  positive  or
negative,  high  proliferation  index  (Ki-67  > 14%),  negative  or
low  positive  PR; (c)  positive  for  HER2  --  overexpressed  or
amplified  HER2,  negative  ER  and PR;  (d)  basal-like  or  TNBC,
also  defined  by  the absence  of ER, PR  and  HER2  amplifica-
tion.  However,  this last  assumption  is  not strictly  accurate
due  as  not all  basal-like  tumors  are completely  TNBC.10,11
This  classification  is  based on  the consideration  that  there
are  two  cell  types  in the  mammary  gland,  luminal  cells  and
basal  cells.  These  two  cell  types  can  be differentiated  by
IHC  tests  as  luminal  cells,  which  express  ER  and  PR  and  that
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Figure  1  Breast  cancer  classification  according  to  immunohistochemistry  cellular  markers  (IHC)  or  according  to  a  combination  of
IHC and  microarray  expression  methods  (gene  signatures).  ER,  estrogen  receptors;  PR,  progesterone  receptors;  HER2,  epidermal
growth receptor  2; CK,  cytokeratin;  EGFR,  growth  factor  receptor.
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are  positive  for  keratins  8/18, while  basal  cells  are  positive
for  keratins  5/6  and  17.12,13
Because  of  the  cost  involved  in  utilizing  microarray  tech-
nology  in  the  clinic,  the most  employed  technique  for  BC
classification  remains  IHC  and  FISH.6,8,14
Between  60%  and  70%  of  all  breast  cancers  correspond
to  positive  ER and  PR  subtypes,6 which  usually  respond  to
targeted  ER  therapy,  such as  selective  ER  modulators  (i.e.
tamoxifen,  or  aromatase  inhibitors)  which reduce  serum
estrogen  concentrations.  Around  15--20% of  BCs  amplify  or
overexpress  the HER2  oncogene.  This  type  of  cancer  is
associated  with  an  incorrect  prognosis  and  the  treatments
specifically  aimed  at HER2  (i.e.  trastuzumab)  have  greatly
improved  results  in women  with  BC  HER2+.15
Prognostic value  of  genomic  signatures in BC
Despite  the  fact that  they  have  not completely  turned
into  routine  methods,  genomic  methods  have been  used
in  research  studies  with  the  purpose  of: (a)  getting  a  bet-
ter  understanding  of  the  nature of  these  variations  of  BC;
(b)  stratifying  patients  through  assessment  of the evolution
of  the  disease  (evaluating  clinical  pathological  character-
istics),  and  (c) understanding  the possible  response  of  the
patient  to treatment  (in  relationship  with  ER, PR, HER2  and
the  proliferation  rate).5,16
Through  global  expression  analysis  with  microarrays,  the
identification  of  gene groups  (genomic  signatures)  has  been
possible,  which  allow  us  to  estimate risk  of  recurrence  of  the
disease  and/or  predict  the response  to  adjuvant  therapy  in
BC  patients  in the  early  stages.17--20 Some  of  these  genomic
signatures  have  been  validated  in large  cohorts  and  have
been  the  precedent  for  some  commercial  genomic  tests,
providing  complementary  information  to  clinicians  in order
to  obtain  a more  precisely  classification  patients  who  has
a  high  risk  of  recurrence,  and  to  offer  more  personalized
attention.
The  first  commercial  signature,  and  the  one  still  widely
distributed  under  its  commercial  name,  is  MammaPrint®
(Agilent,  Amsterdam,  Holland).  This  signature  measures
mRNA of  70  gene  expression  and  was  approved  by  the US
FDA  and  by  regulators  in the  EU  as  an essay  with  prognostic
value  in  patients  with  BC  who  are under  61  years  of  age,
in  an  I/II  stage,  with  negative  lymph  nodes  or  one  to  three
positive  lymph  nodes.  In addition to  accurately  identifying
patients  who can  safely  avoid  adjuvant  chemotherapy.17,21
MammaPrint  stratifies  patients  into  low-risk  or  high-risk
groups.17 However,  even  though  discrimination  is  good  for
ER+  cancers,  it is  not  the  same  with  ER−  cancers,22,23
limiting  its  clinical  value  to  a subgroup  of  patients.
Another  widely  distributed  and  commercially  available
assay  is Oncotype  DX® test  (Genomic  Health,  Redwood  City,
CA,  U.S.).  This test is  used to  classify  patients  with  Lumi-
nal  A  and  B  BCs,  as  well  as  HER2+  subtypes  (though  not
TNBC),  since  it  has  been  designed  to assess  genes  related
to  ER,  proliferation  genes,  HER2  genes,  and  genes  related
to  invasion,  among  others.19 This  test  allows  the  oncolo-
gist  to  discern  whether  or  not chemotherapy  treatment  will
be  beneficial.  This  essay  measures  the  21-gene  expression,
which  provides  information  of  the recurrence  of  the  disease
through  a  scoring  system  from 0  to  100,  stratifying  patients
into  low-risk  (score  <18),  intermediate  risk  (score  18--30)  or
high  risk  (≥31)  groups.19,20
A third test,  consisting  of  an algorithm  for the intrinsic
molecular  classification  of  BC,  has  been  nominated  PAM50
(Fig.  2). This  was  designed  to  improve  IHC  and microar-
ray  classification  aggreance.24 This  50-gene  signature  can
classify  BCs  as luminal  A,  luminal  B,  HER2  and  basal-like.
The  PAM50  score  was  designed  with  the  purpose  of  trans-
lating  the  different  intrinsic  subtypes  into  an associated
prognostic  value.24 An  application  of  this  score  is  the iden-
tification  of  patients  who  may  benefit  from the  weekly
addition  of  paclitaxel  to  conventional  chemotherapy  with
anthracycline  as  an  adjuvant  treatment  of  operable  BC  with
positive  lymph  nodes.25 In  2013,  Prosigna  (Seattle,  Wash-
ington,  U.S.) started commercializing  a diagnostic  kit  which
qualifies  mRNA  expression  of  the 50  genes  used  by  the  algo-
rithm  in order  to  calculate  the risk  of  recurrence.26
In addition  to  these  tests,  which  are the  most  commonly
distributed,  there  are  others  in  the market,27--29 where  the
common  denominator  is  the  measurement  of  gene expres-
sion  of proliferation  related  genes.  It is important  to  mention
that  these  multiple-gene  assays  are  for  the  most  part,  if not
exclusively,  applicable  to  luminal  BC,  thus  stressing  once
more  the  need to  search  for and  identify  markers  with  pro-
gnostic  value  and  response  to  treatment  in BC  patients  with
negative  hormonal  receptors  or  HER2  amplification.
Triple negative breast cancer  (TNBC)
Since  1997,  the National  Comprehensive  Cancer  Network
(NCCN)  has  gathered  data  of  women  with  newly  diagnosed
breast  cancer,  representing  many  institutions  around  the
U.S.  HER2  by  IHC’s status  was  added  to  the data  from  the
NCCN  as  a routine  element  in the year  1999,  and HER2  status
through  fluorescent  in situ hybridization  (FISH)  was  added
in  2001.  The  term  ‘‘Triple  Negative  Breast  Cancer’’  (TNBC)
appeared  for the first  time  in the literature  in  2005.30 Due
to  the lack  of  effective  therapeutic  options,  many  studies
have  focused  on  the  understanding  of  the  biology  of  TNBC  for
the  selection  of  biomarkers  and therapeutic  targets.  In this
review,  we  will  focus  on  making  a compilation  of molecular
and  gene  studies  in reference  to this  BC  subgroup.
TNBC  risk factors
TNBC  makes  up  about  15--20%  of  all BCs  and  follows  an
aggressive  clinical  course,  including  a  high  incidence  of  vis-
ceral  and  nervous  metastases,  compared  to  BCs  positive  to
hormone  receptors,  TNBC  is  more  frequently  associated  with
BRCA1  and, to  a  lesser  extent,  BRCA2  mutations.31,32 It  has
also  been  associated  with  a high  local  recurrence  rate  at
three  years  after  treatment,  and  a  high  death  rate  at 5 years.
Upon  long-range  metastasis,  the  survival  rate  is  poor.33 Dif-
ferently  from  other  subtypes  of  BC  (Luminal  A, B and HER2),
where  early  pregnancy  has been  recognized  as  a protective
factor  against  BC,  gestation  appears  to  be an  important  risk
factor  in the development  of  the  triple  negative  phenotype.
In  a study  by  Phipps  et  al.,34 they  reported  that  women  who
had  more  children  (three  or  more)  had a  greater  risk  (1.4
times)  of  TNBC.  Later,  a  study  by  Tamimi  et  al.35 reaffirmed
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Figure  2 Breast  cancer  classification  example  using  PAM50.
that  multiple  pregnancies  were associated  with  an increased
risk  of developing  TNBC.
Other  behaviors  associated  with  the triple  negative  sub-
type  are  a lack  of  lactation,36 and  various  studies  have
made  an  association  between  TNBC  and  a high  body mass
index  (BMI),  a metabolic  syndrome,  type 2 diabetes,  obe-
sity  and/or  insulin  resistance.37--43 Consequently,  patients
with  TNBC  are  the  group  with  the  worst  prognosis,  which
is  important  to  consider  in  a  country  like  Mexico,  which has
an  elevated  prevalence  of  obesity  and  metabolic  syndrome.
Racial  ancestry  has  been  shown  to  have  an important
relation  to  TNBC,  since  21%  of  Afro  American  BCs  have
been  classified  as  TNBC  (compared  to  15%  of the  Caucasian
population).44--46 The  Hispanic  population  has  also  shown  a
high  incidence  of this  cancer  subtype,  with  a  frequency  of
21.3%  in  Peru,47 27%  in Brasil,48 24.1%  in Venezuela49 and
23.1%  in  Mexico.50
TNBC  presents  a high  rate  of  proliferation51 and  is  highly
aggressive.32,52--54 In  a  study  by  Sorlie  et al.,  in which  the
response  to  an uniform  treatment  was  evaluated,  they
reported  differing  results  between  patients  belonging  to
groups  of  distinct  subtypes.  Among  these  results  exist  a
report  that  patients  with  TNBC  had  the worst  prognosis  by
a  significant  margin  when compared  to  patients  with  can-
cers  that  had  positive  hormone  receptors.11 In a later  study,
Dent  et  al.  compared  the clinical  history,  outcome  and  the
nature  of  the disease  in women  with  TNBC  to women  with
other  subtypes.  The  results  showed  that  TNBC  had  a  low
survival  rate  and  a high  rate  of  long-distance  metastasis
after  treatment.52 Due  to  TNBC’s  aggressive  course,  these
types  of cancers  can  be  highly  sensitive  to  cytotoxic  med-
ications.  The  proportion  of  patients  who  reach  a  complete
pathological  response  (CPR)  after  treatment  were  found  to
be  30--45%,55,56 and  the patients,  which  achieved  a CPR
had  excellent  long-term  results,  with  a  global  survival  rate
higher  than  90%.  In  addition,  if CPR  is  achieved,  patients
with  TNBC  or  other  types  of  BC  had a similar  survival  rate.
However,  those  patients  with  TNBC  who  presented  with  a
residual  disease  had worse  results  than  patients  with  other
types  of  BC.45,57 The  aggressiveness  of  TNBC  and the  short-
age  of specific  therapeutic  options  underline  the  need  to
understand  the ways  in which  this type  of  cancer  develops.
Molecular  classification  of TNBC  subtypes
In 2007,  Kreike  et  al. reported  that  TNBCs  were  synony-
mous  with  basal  type molecular  cancers.58 However,  as  we
mentioned  before,  it has  been  proven  that TNBC’s  molec-
ular  biology  is  diverse  and heterogenous,59 and that TNBC
is  not  an ideal  substitute  for  the  basal  phenotype.  In  2011,
Lehmann  et al.60 identified  6 subtypes  of  TNBC,  as  well  as
1  unstable  subtype.  The  six subtypes  included  two  basal
like  (BL1 and  BL2),  one immunomodulatory  class,  one  mes-
enchymal  class,  one  mesenchymal  stem  cell  (MSC)  class,  and
one  luminal  androgen  receptor  (LAR)  class.  In  addition,  gene
expression  analysis  allowed  the authors  to  identify  the  cell
lines  representative  of  each  TNBC  subtype  to  later  evaluate
their  response  to  different  medications.
BLI:  Cancers  in this  group  are characterized  by  their  rapid
cell  division,  with  an increased  proliferation  rate  and  loss
of  cell  cycle  control.  Due  to  this,  they  present  an  elevated
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expression  (mRNA)  of  Ki67  and  respond  to  antimitotic
agents.
BL2:  These  cancers  present  the  expression  of EGFR,  TP63,
MET,  etc.  and  involve  activation  of  glycolysis  and  gluconeo-
genesis  routes.
IM:  They  are  composed  of response  cells  from  the  immune
system,  and  present  antigens  and  cytokine  expression.
They  overlap  with  medullary  breast  cancer  with  a favorable
prognosis.
M  and  MSL:  These  groups  present  epithelial-mesenchymal
transition  markers,  including  angiogenesis  (VEGFR2)  and
most  likely  respond  to  desatinib  (TK  inhibitors)  and  mTOR.
LAR:  This  group  is  characterized  by  the expression  of
androgen  receptors  (AR).  They  are RE  negative,  but
maintain  an  elevated  hormonal  component,  regulated  by
steroid  synthesis,  porphyrin  metabolism  genes  and  andro-
gens/estrogens.  The  AR’s  expression  is  up  to  nine  times
more  than  the  other  groups,  and  are prime  candidates  for
anti-androgen  therapies.
The  signaling  pathways  obtained  by  the  study  are  poten-
tial  pharmacological  targets  in these  cell  models  to  that
analysis  of these  distinct  genetic  signatures  can be  used to
select  a  therapy.  In  general,  it  was  observed  that  the BL1
and  BL2  subtypes  respond  well  to  cisplatin,  and  that  the
M  and  MSL  types  respond  well  to NVP-BEZ235,  a  PI3K/mTOR
inhibitor  and  dasatinib  (a tyrosine  kinase  inhibitor).  The  LAR
subtype  was  only  sensitive  to bicalutamide  (an  androgen
receptor  agonist).
Later,  Burstein  et al.61 confirmed  four of the subtypes
reported  by Lehmann  with  the base  DNA  profiles  or  the sin-
gle  nucleotide  DNA  markers  from  198 TNBC  samples:  one
luminal  androgen  receptor  type,  one mesenchymal  type,
and  two  basal  types.  These  studies  by  Burstein  and  Lehmann
suggested  the  existence  of  at least 4  TNBC  subtypes
(Fig.  3).
The  search  for  TNBC  biomarkers
Various  expression  studies  have  been  performed  on  TNBC
with  the  aim  of  identifying  therapeutic  targets,  which have
been summarized  in Table  1. This  summary includes  the
characteristics  of  each study  and  the  selected  differentially
expressed  principal  genes.  This  table shows  the variability  of
the  data  obtained  from  each study.  This  indicates  that  vali-
dation  of these  possible  molecular  targets  is  necessary  and
even  more  studies  are required  to  find  efficient  biomarkers
for  the treatment  of  TNBC.
TNBC  is  a subtype  of BC  with  a very  heterogeneous  behav-
ior  which,  based  on  gene expression  analysis  by  microarray,
was  classified  by  Lehmann  into  six  distinct  groups.  This  sub-
classification  is  not  only  useful  to  the better  understanding
of  this  disease,  but  also  to  identify  new  molecular  targets
for  its  treatment.  Following  are some  of the proteins  which
have been  identified  in these  TNBC  groups  as  potential  ther-
apeutic  targets.
EGFR:  This  is  one  of  the  principal  receptors,  and  plays  an
important  role  in  the  survival  of  the  tumor.  It  is  a  marker
of  cellular  proliferation,  angiogenesis,  metastasis  and apo-
ptosis  inhibition.
VEGF:  This  is  the  principal  marker for  angiogenesis.  It
induces  proliferation  and maintains  the integrity  of  the
cell.
C-kit  and  basal  cytokeratins:  C-kit  unites  with  the
receptor  of  a  growth  factor,  stimulates  survival  and differ-
entiation,  and  induces  invasiveness  in the cancerous  cell.
The  basal  cytokeratins  are intermediate  filament  proteins.
Their  expression  is  constant  when epithelium  undergoes
transformation.
P53:  suppressor  protein  important  in cell  cycle  regulation
and  tumor  apoptosis.
hKi67:  A cellular  proliferation  marker  which  is  present  in
the  nucleus  during  interphase  and  mitosis.  Ki67  expression
TN
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Figure  3  Lehman’s  triple  negative  breast  cancer  classification,  gene  ontology  and  proportion.  TNBC,  triple  negative  breast  cancer;
BL1, basal  like  1; BL2,  basal  like  2; IM,  immunomodulatory;  M,  mesenchymal;  MSL,  mesenchymal  stem  cell-type;  LAR,  androgen
luminal receptor;  MET,  mesenchymal  epithelial  transition.
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Table  1  Main  genes  reported  from  researches  which  analyze  TNBC  gene  expression  profiles.  TNBC,  triple  negative  breast  cancer;  nTNBC,  non-triple  negative  breast  cancer.
Author  Observation  Main  genes  Signature
objective
Experiment  design
Sample
characteristics
Comparison
Rody,  201159 16  meta-genes:  basal
phenotype,  androgen
receptor  signaling,
diverse  immune  cells,
stroma,  Claudine  CD24,
blood  cell markers  and
adipocytes,
inflammation  and
angiogenesis  (VEGF)
EPHB3,  GABRP,  AR,  FOXA1,  IgG,  TCR,  LCK,  ITK,  HLA-DR,
-DM, -DP,  -DQ,  HLA-A,  -B,  -C,  -E,  -F,  -G, OAS1,  OAS2,
OAS3, MX1,  Decorin,  Osteonectin,  Fibronectin.
COL5A1,  CLDN3,  CLDN4,  CD24,  ELF3,  BUB1,  CDC2,  STK6,
BIRC5,  TOP2A,  HBA1,  HBA2,  HBB, FABP4,  PLIN,  ADIPOQ,
ADH1B,  VEGF,  adrenomedulina,  ANGPTL4,  IL-8,  CXCL1,
CXCL2, HOXA-4,  -5, -7,  -9, -10,  -11,  Histones  H2A,  H2B
Prognosis/
therapeutic  target
Public  database  394  TNBC
Karn, 201171 2 signatures  (26  main
genes)
IL8,  SCD,  AQP3,  SERPINE1,  LYPDC1,  PGK1,  SEC23A,
SNAPC1,  SNF7DC2,  SORT1,  SPOCK,  SRPX2,  STC1,  STMN2,
SYNCRIP,  TAX1BP3,  TBC1D22B,  TGFB2,  TGFBI,  THBS1,
TIAM1,  TLE6,  TNFAIP1,  TNFRSF10B,  TRIM23,  TSGA10,
TXNDC9,  U2AF1L1,  ULBP2,  UQCRC1,  VLDLR,  VMD2,
WFDC1,  WWTR1,  ZA20D1,  ZP2
Prognosis  Public database  394  TNBC
Cascione, 201372 2×  microRNA  signatures
and  4 gene  subgroups
miR-16,  155,  125b,  374a  and  miR-16,  125b,  374a,  374b,
421, 655,  497
Molecular  subgroup  1:  SPP1,  MMP9,  MYB12,  BIRC5,
TOP2A,  CDC2,  CDKN2A.  Molecular  subgroup  2: BCL2,
EGF, ERBB4,  AR,  ESR1,  IL1A,  FGFR2,  WT1,  MYC,  FGF2,
AKT1, CASP10.  Molecular  subgroup  3: MET,  L1CAM,
IGFBP3.  Molecular  subgroup  4:  TIMP1,  TIMP2,  CDKN1A,
CCND2,  MAP3K8,  CAV1,  LAMB1,  JUN,  CEBPA
Sub-classification/
therapeutic  target
Paraffin-
embedded
tissue
TNBC  vs Adjacent
tissue  and  lymph
node  injuries
Komatsu, 201373 322  unregulated  genes  Main  overexpressed  genes:  UBE2C,  S100P,  UCHL1,
PTTG1, UBE2T,  SIX1,  PRC1,  TOP2A,  HORMAD1,  FABP5,
ATAD2.  Main  sub-expressed  genes:  PIP,  DNAL11,  WIF1,
SCUBE2,  TBC1D9,  TFF3,  ERBB4,  GATA3,  MLPH.  LAMAB,
LTBP2,  LIFR,  LRP2,  MASP2,  MATN2,  MGP,  NTN4,  NRG1,
PTHLH,  PI15,  PLAT,  PDGFA,  PTN,  PIGR,  PIP,  SCGB1D1,
SCGB1D2,  SCGB3A1,  SEMA3G,  STC2,  THSD4,  TFF3.
Therapeutic  target  Fresh  tissue  TNBC  vs epithelial
ductal  cells
Al-Ejeh, 201474 8 genes  MAPT,  MYB,  MELK,  MCM10,  CENPA,  EXO1,  TTK  and  KIF2C  Prognosis/
therapeutic  target
Meta-analysis  CMTN  vs CMnTN
Khaled, 201575 1 gene  BCL11A  Therapeutic  target  Public data
base
CMTN  vs CMnTN
He, 201576 3 genes  DUSP1  and  FOXA1.  DUSP1  Therapeutic
targets
Public  data
base
CMTN  vs CMnTN
Pacheco-Velazquez,
201477
4 genes  HIF-1  +  c-MYC  +  2OGDH  +  E-cadherina  Prognosis  Fresh  tissue  CMTN  vs CMnTN  vs
Normal  tissue
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in  normal  mammary  tissue  is <3%.  The  expression  of  TNBC
can  elevate  it  up  to  80%.  It  self-expresses  particularly  in
RE-negative  cells.  It is  associated  with  an unfavorable  prog-
nosis.
PARP:  A  family  of  cell  signaling  enzymes.  18  PARP  pro-
teins  have  been  identified.  PARP1  is  responsible  for  the
majority  of  its  functions.  It  is  a  DNA  damage  sensor  and
plays  an  important  role  in its  repair  and  in  responses  to
inflammation,  ischemia  and oxidative  stress.  In cells  with
a  BRCA  mutation,  PARP  inhibition  contributes  to  cell  death
by apoptosis.
Hsp90:  A  cellular  chaperone,  it stabilizes  the conformation
of  many  labile  proteins,  such as  steroid  receptors,  CDK4,
RAF-1  and  AKT,  etc. PU-H71  is  a  cyclin  inhibitor  which  has
been  shown  to  be  useful  in  some TNBC  models.
COX2:  This  protein  is  expressed  by  the  inflammatory  stim-
ulus  and  its expression  is  associated  with  an unfavorable
prognosis.
TK:  A  regulatory  protein  which  helps  the  cell  grow  and
differentiate  itself.
mTOR:  The  over-expression  of  these  proteins  (PI3K/mTOR)
is  associated  with  a poor  response  to  treatment  with  hor-
mones  and  trastuzumab.
TNBC  treatment
Women  with  TNBC  are  not  able  to  take  endocrinology
therapies  neither  HER2  targeted  therapies,  hence  treat-
ment  options  are  limited  to  surgery,  radiotherapy  and
chemotherapy,62,63 being chemotherapy  the  standard  treat-
ment  of  TNBC.  In  the past  two  decades the use  of  more
aggressive  therapy  has  produced  a clearer  improvement
in  quality  of  life;  however,  there  is  a  consensus  opinion,
which  considers  that  it would be  impossible  to  improve  these
results  if  this  cytotoxic  therapy  remained  the only option  to
be  offered  to  these  patients.  For this  reason,  there  is  an urge
to  find  new  ‘‘intelligent  drugs’’  capable  of  solving  chemore-
sistance  and reducing  the risks  of  chemotherapy  in  patients
who  do  respond.  The  greatest  obstacle  to  find actionable
targets  is  the  vast  heterogeneity  both  inter  and intra-tumor
of  the  TNBC.  In  fact,  several  years  of study have  failed  to
prove  a  unified  alteration  which  may  serve  as  targets  of  a
targeted  therapy.
Several  researches  about  TNBC  describe  genomic  sig-
natures  involving  affected  signaling  pathways,  including
cellular,  immunologic  and  metabolic  processes  like  --  basal
keratin  differential  expressions,  interferon  proliferation  and
regulation  routes,  low  expression  in Claudine,  mesenchy-
mal  epithelial  transition,  androgen  receptor  expression
(AR)  and  angiogenesis  activation  (VEGF).58--60 These  findings
have  revealed  potential  molecular  targets,49 and different
drug  types  are  currently  found  under  investigation,  which
can  basically  be  defined  in four  groups:  (1)  agents  which
cause  damage  to  DNA  (i.e.  cisplatin,  cyclophosphamide),
(2)  agents  which  inhibit  poly  (ADP-ribose)  polymerase
(PARP  inhibitors),  (3)  tyrosine-kinase  inhibitors  and  (4)
agents  which  inhibit  downstream  signaling  pathways  (mainly
PI3K/AKT).64 Down  below there  are  the descriptions  of  treat-
ments  which  have been  proven  depending  upon  identified
therapeutic  targets  in TNBC.
• Bevacizumab:  Anti-VEGF  (vascular  endothelial  growth
factor)  monoclonal  antibody  that  blocks  angiogenesis;
although,  a  lack  of  efficiency  as  well  as  a toxicity  incre-
ment  have  been  observed.65
•  Olaparib/iniparib:  PARP  inhibitors  in patients  with  muta-
tions  in BRCA1/2,  they  have  also  been  widely  studied
since  they  have  shown  to  have  anticancer  selective  activ-
ity  in  BRCA1  and  BRCA2-deficient  cancers;  nevertheless,
the  relevance  of the  inhibition  of  these enzymes  has  yet
to  be  confirmed.66
•  Cetuximab:  Anti-EGFR  monoclonal  targeted  antibody,  it
has  been  evaluated  as  monotherapy  or  with  a platinum-
based  therapy  (carboplatin).  Even  though,  at first, this
therapy  seemed  to  be very  promising,  it has  proven  very
modest  results.67
•  mTOR  inhibitors  (mammalian  target  of  rapamycin)  --
mTOR  is  a  PI3K  signaling  pathway  effector  regulated  by
AKT  and  suppressor  of  PTEN  tumors.  PI3K  pathway  pro-
teins  are frequently  affected  by  mutations  in mammary
carcinomas,  and the  loss  of  PTEN  is  a  frequent  discovery
in  TNBC;  thus, increasing  the activation  of  mTOR  in the
diseases.68 It is  for  this  reason  that today,  mTOR inhibitor
drugs  have  been  under  evaluation.69
•  Bicalutamide/enzalutamide  (‘‘anti-androgen’’  targeted
therapy):  Some  preclinical  studies  showed  that  lumi-
nal  TNBC  which  expresses  the androgen  receptor  (AR)
is  sensitive  to  androgen  deprivation.  Bicalutamide  as
monotherapy  demonstrated  a  clinical  benefit  of  19%  of the
AR  positive.70 Today,  a  phase  II  study  is  evaluating  enza-
lutamide’s  safety  and  efficacy  in TNBC  and  AR  positive
patients.  Results  are  yet  to  be  seen.
Targeted  therapies  against some identified  biomarkers  in
TNBC  have  not  proven a significant  improvement,  the prob-
lem  has  been  the lack  of  dependable  predictive  biomarkers,
which  is  essential  before  any  of  these treatments  can  be
introduced  in clinical  practice.
Conclusions
TNBC  is  usually  the most  aggressive  type of cancer  and  it is
linked  to  the  highest  mortality  rate  in comparison  to  other
types  of BC.  Numerous  advances  in  the understanding  of  this
cancer  have  been  made.  Reported  genomic  signatures  to
date  reflect  the  heterogeneity  of  the triple negative  pheno-
type,  at the same  time  have allowed  for  a  TNBC  classification
into  6  clinically  relevant  subgroups.  One  of  these  subgroups
has  a  strongly  immune  component.  Another  subgroup  shares
biological  characteristics  with  mutations  in  genes  BRCA1/2
with  deficiency  in  DNA  repair.
While  several  TNBC  biomarkers  are reported  in the lit-
erature  every  year,  only few  have  exceeded  validation  to
justify  its  use  in clinical  practice.  The  reason  for  this  deteri-
oration  may  be due  to  the  fact  that  while  strong  associations
often  derive  initially  between  the  expression  of  a putative
biomarker  and  the stage  of  the  disease,  candidate  markers
do  not  often  have any  relevant  and  significant  functions  of
the  disease  in clinical  laboratory  and therapeutic  practice.
For  TNBC  specifically,  different  research  groups  that used
the information  generated  by  microarrays  obtained  results
varying  from  one  group  to  another  and  in some  cases  these
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results  have  not  been  able  to  be  validated.  This  could  be  a
result  of  the  inherent  heterogeneity  of TNBC  or  each  exper-
iment  design’s  own  limitations,  such  as:  (1)  the  use  of  large
data  base  retrospective  cohorts,  where  TNBC’s  classification
is  based  solely  on  the  information  obtained  from  the gene
expression  profile  data,  this methodology  is  not the standard
in  clinical  practice.  Also,  this information  shows  limita-
tions  due  to  how  varying  the data  collection  and  sample
management  methods  are used  (in  some  cases  paraffin-
embedded  tissue  was  utilized,  others  utilized  fresh  tissue,
etc.)  to feed  the databases  that are afterwards  referenced
by  other  researchers;  (2)  limited  gene  expression  analysis
of  a  determined  number  of  genes,  instead  of  conducting  a
global  analysis  of  gene  expression;  (3)  previous  works  and
researches  compared  TNBC  gene  expression  profiles  vs  other
BC  subtypes,  or  TNBC  vs  normal tissue,  which  does  not  unify
stratification  criteria.
In Mexico,  there  are few  research  papers  which  report
the  analysis  of TNBC  expression  profiles  This  is  concerning,
since  this  type  of  BC  jeopardizes  a  considerable  amount  of
cases  among  the Mexican  population,  hence it is  necessary
to  increase  efforts  in the  search  of  biomarkers  or  possible
therapeutic  targets  which  can  be  validated  in our  popula-
tion.
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